Your browser doesn't support javascript.
loading
Mass Drug Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis.
Schneider, Zachary D; Shah, Monica P; Boily, Marisa C; Busbee, Alexandra L; Hwang, Jimee; Lindblade, Kim A; Gutman, Julie R.
Afiliación
  • Schneider ZD; Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Shah MP; Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Boily MC; Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Busbee AL; Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Hwang J; U.S. President's Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Lindblade KA; Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Gutman JR; Global Malaria Programme, World Health Organization, Geneva, Switzerland.
Am J Trop Med Hyg ; 110(4_Suppl): 17-29, 2024 04 02.
Article en En | MEDLINE | ID: mdl-38118174
ABSTRACT
Malaria remains a significant cause of morbidity and mortality, even in low-transmission settings. With the advent of longer acting, more effective, and well-tolerated antimalarials, there is renewed interest in the efficacy of mass drug administration (MDA) to accelerate to elimination. We conducted a systematic review and meta-analysis to assess the efficacy of MDA to reduce the incidence and prevalence of Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) infection. From 1,044 articles screened, 14 articles, including 10 randomized controlled trials (RCTs), were identified. Five included data on Pf only; five included Pf and Pv. Two of the Pf studies were conducted in areas of high-moderate transmission, the remainder were in areas of low-very low transmission. In higher transmission areas, MDA reduced incidence of Pf parasitemia (rate ratio = 0.61, 95% CI 0.40-0.92; moderate certainty) 1 to 3 months after drug administration; no significant effect of MDA on Pf parasitemia prevalence was detected 1 to 3 months post-MDA (risk ratio [RR] = 1.76, 95% CI 0.58-5.36; low certainty). In lower transmission settings, both incidence and prevalence of Pf parasitemia were reduced 1 to 3 months post-MDA (rate ratio = 0.37, 95% CI 0.21-0.66; RR = 0.25, 95% CI 0.15-0.41, respectively). Pv prevalence was reduced 1 to 3 months post-MDA (RR = 0.15, 95% CI 0.10-0.24); there were no RCTs providing data on incidence of Pv. There was no significant effect of MDA at later time points. MDA may have short-term benefits; however, there was no evidence for longer term impact, although none of the trials assessed prolonged interventions.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Malaria Vivax / Malaria Falciparum / Administración Masiva de Medicamentos / Antimaláricos Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Am J Trop Med Hyg Año: 2024 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Malaria Vivax / Malaria Falciparum / Administración Masiva de Medicamentos / Antimaláricos Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Am J Trop Med Hyg Año: 2024 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos